Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Seres Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2010 · IPO 2015 Thoroughbred

A clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome

Valuation
$109M
Market cap · May/2026
Revenue
$789K
Latest reported FY

Investors

3 investors on Seres Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Flagship Pioneering
Enso Ventures
Series B+ 1 investor entered at this stage
Nestlé Health Science

Global footprint

Where Seres Therapeutics has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States98.5%
🇨🇭 Switzerland0.8%
🇳🇱 Netherlands0.8%
3 countries shown
Web traffic by country
5.3K monthly visits
across markets
🇺🇸 United States69.8%
🏳️ Korea17%
🏳️ Republic of9.4%
🇮🇳 India1.9%
🇨🇦 Canada0%
Top 5 markets shown

Market sentiment

What the market is saying about Seres Therapeutics

An AI-synthesized read of the highest-engagement posts about Seres Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Seres Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.